PoreSkin
Devicea human acellular dermal matrix
NCT Number: NCT02486874
PoreSkin, a human acellular dermal matrix (hADM) manufactured by Faculty of Medicine, Chulalongkorn University, is the first human dermal substitute developed in Thailand. It is a permanent dermal substitute aiming to reduce skin contracture. The objective of this study is to assess the safety and ability in achieving durable and cosmetic coverage of PoreSkin.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
a human acellular dermal matrix
Time frame: 1 month
Time frame: 1 month
erythema, infection, fever, and rejection of the graft
Time frame: 1 month
evaluated by Vancouver Scar scale
Looking for future studies?
Notify MeChulalongkorn University
Other
Clinical Evaluation of PoreSkin: A Human Acellular Dermal Matrix
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07815418
Acute-On-Chronic Liver Failure, Acute-on-Chronic Liver Failure (ACLF)
Wuhan, Hubei, China
View Trial DetailsNCT07487649
Brain Diseases, Central Nervous System Diseases
Edirne, Turkey (Türkiye)
View Trial DetailsNCT05850728
Acquired Immunodeficiency Syndrome, Antiretroviral Therapy
Seattle, Washington, United States
View Trial DetailsNCT06766851
Arthrocentesis, TMJ Disc Disorder
Eskişehir, Turkey (Türkiye)
View Trial Details